25 completed. 25 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 25 |
| Phase 2 | 1 | Completed 1 |
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer Biological : Toripalimab Drug: Axitinib, sunitinib - Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 | Phase 3 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 421 | 2020-08-20 | 2025-11-28 |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) Pembrolizumab, Epacadostat, Sunitinib - Renal Cell Carcinoma (RCC) | Phase 3 | Completed | Incyte Corporation | 129 | 2017-12-07 | 2026-05-22 |
| A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Nivolumab, Cabozantinib, Sunitinib - Renal Cell Carcinoma | Phase 3 | Completed | Bristol-Myers Squibb | 701 | 2017-07-23 | 2026-08-24 |
| Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) Pembrolizumab, Axitinib, Sunitinib - Renal Cell Carcinoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 861 | 2016-09-16 | 2026-02-02 |
| A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib - Renal Cell Cancer | Phase 3 | Completed | Pfizer | 886 | 2016-03-23 | 2025-07-30 |
| A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Sunitinib - Renal Cell Carcinoma | Phase 3 | Completed | Hoffmann-La Roche | 915 | 2015-05-20 | 2023-01-30 |
| Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Nivolumab, Ipilimumab, Sunitinib - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 3 | Completed | Bristol-Myers Squibb | 1096 | 2014-10-16 | 2026-05-27 |
| Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib Masitinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 3 | Completed | AB Science | 258 | 2012-04-01 | 2020-12-08 |
| IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma Sunitinib, GM-CSF, Cyclophosphamide - Metastatic Renal Cell Carcinoma | Phase 3 | Completed | Immatics Biotechnologies GmbH | 339 | 2010-12-01 | 2017-10-12 |
| Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer sunitinib malate, Placebo, transarterial chemoembolization - Liver Cancer | Phase 2 / Phase 3 | Completed | Federation Francophone de Cancerologie Digestive | 78 | 2010-07-01 | 2022-03-18 |
| Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer pazopanib, sunitinib - Carcinoma, Renal Cell | Phase 3 | Completed | Novartis Pharmaceuticals | 169 | 2010-05-17 | 2017-04-17 |
| Clinical Trial to Assess the Importance of Nephrectomy Nephrectomy, Sunitinib alone - Metastatic Renal Cell Carcinoma | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 452 | 2009-09-09 | 2025-09-05 |
| Sequential Study to Treat Renal Cell Carcinoma Sunitinib (Sutent), Sorafenib (Nexavar) - Renal Cell Carcinoma | Phase 3 | Completed | Sponsor GmbH | 272 | 2009-01-01 | 2014-04-23 |
| Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma Pazopanib, Sunitinib - Carcinoma, Renal Cell | Phase 3 | Completed | Novartis Pharmaceuticals | 1110 | 2008-08-14 | 2025-03-30 |
| Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment - Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 210 | 2008-06-15 | 2026-06-23 |
| A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Sunitinib malate, Placebo - Kidney Neoplasms | Phase 3 | Completed | Pfizer | 674 | 2007-08-01 | 2018-09-21 |
| A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone erlotinib, sunitinib, placebo - Carcinoma, Non-Small Cell Lung | Phase 3 | Completed | Pfizer | 960 | 2007-07-01 | 2013-10-29 |
| Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer 5 fluorouracil, irinotecan, levo- leucovorin - Metastatic Colorectal Cancer | Phase 3 | Completed | Pfizer | 768 | 2007-06-01 | 2015-03-30 |
| Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib - Gastrointestinal Stromal Tumors | Phase 3 | Completed | Novartis Pharmaceuticals | 248 | 2007-03-01 | 2012-06-12 |
| A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer Sunitinib + Capecitabine, Capecitabine - Breast Neoplasms | Phase 3 | Completed | Pfizer | 442 | 2007-02-01 | 2012-06-26 |
Showing 20 of 25. Sign in to see all of them.
Carcinoma, Renal Cell (13) · Breast Neoplasms (3) · Gastrointestinal Stromal Tumors (3) · Carcinoma, Non-Small-Cell Lung (2) · Kidney Neoplasms (2) · Neoplasms (2) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Kidney Diseases (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Patient Preference (1)
Pfizer (9) · Novartis Pharmaceuticals (3) · Bristol-Myers Squibb (2) · National Cancer Institute (NCI) (2) · AB Science (1) · Assistance Publique - Hôpitaux de Paris (1) · Federation Francophone de Cancerologie Digestive (1) · Hoffmann-La Roche (1) · Immatics Biotechnologies GmbH (1) · Incyte Corporation (1) · Merck Sharp & Dohme LLC (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Sponsor GmbH (1)
United States (18) · Germany (17) · Italy (17) · France (15) · Spain (15) · United Kingdom (15) · Canada (13) · Australia (12) · Poland (11) · Netherlands (10) · Russia (10) · South Korea (10) · Czechia (9) · Austria (7) · Belgium (7)
Arnaud Mejean, MD PhD (1) · Axel Le Cesne, M.D., Ph.D (1) · Brian Rini, MD (1) · Mark A Socinski (1) · Mark Jones, MD (1) · Mohamed Hebbar, MD (1) · Naomi S Balzer-Haas (1) · Tim Eisen, MD (1)
PMID 37146227, PMID 26457466, PMID 33947608, PMID 37526095, PMID 17046465, PMID 17215529, PMID 20104222, PMID 21858552, PMID 23358972, PMID 23857972, PMID 23964934, PMID 24338498, PMID 24687826, PMID 25577718, PMID 25952317, PMID 26685869, PMID 26702763, PMID 26969090, PMID 27000445, PMID 27238653, PMID 27718781, PMID 27720136, PMID 28161554, PMID 28278333, PMID 28410911, PMID 28945839, PMID 28967554, PMID 29374054, PMID 29439857, PMID 29562145, PMID 29654533, PMID 29773662, PMID 29788981, PMID 29853320, PMID 29860937, PMID 30412222, PMID 30658932, PMID 30779529, PMID 30779531, PMID 31079938, PMID 31427204, PMID 31601514, PMID 31633185, PMID 31703971, PMID 31992108, PMID 32127394, PMID 32171288, PMID 32339648, PMID 32576496, PMID 32582758
2014 (2), 2017 (2), 2008 (1), 2015 (1), 2016 (1), 2023 (1), U10CA021115 (1), U10CA031946 (1), U10CA180820 (1), U10CA180821 (1)